Determining potential immunomodulatory drug efficacy in sepsis using ELISpot

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 18, 2025

This study evaluated the ability of ELISpot to identify potential immuno-modulatory drug therapies in sepsis. was performed ex vivo on whole blood from septic patients and healthy controls. Innate adaptive immunity were by production TNF-α IFN-γ, respectively. Drug efficacy determined their effects modulate both number cytokine-producing cells amount cytokine produced per cell. The corticosteroid dexamethasone for its down IFN-γ production. TLR7/8 agonist resiquimod (R848) T cell stimulants IL-7 anti-PD-1 mAb tested enhance immunity. LPS increased total 1,549% 1,829%, Conversely, diminished responses or 75% 61%, IL-7, but not markedly subjects (121%) (82%). Dexamethasone also reduced anti-CD3/CD28 stimulated 69%; while ameliorated dexamethasone-induced suppression. significantly enhanced lymphocyte function over 90% patients. can reveal host immune response patterns drugs selectively down- up-regulate patient Furthermore, detect effect specific independently regulate innate could enable precision-based

Language: Английский

---

Determining potential immunomodulatory drug efficacy in sepsis using ELISpot

Published: July 16, 2024

ABSTRACT Purpose This study evaluated the ability of ELISpot to identify immuno-modulatory drug therapies for their potential efficacy in patients with sepsis. Methods was performed using diluted whole blood from 61 septic and 48 healthy matched controls. Innate adaptive immunity were by ex vivo stimulated production TNF-α IFN-γ respectively. Potential determined drugs’ effects increase or decrease number cytokine-producing cells amount cytokine produced per cell as spot size intensity. The corticosteroid dexamethasone its down modulate production. TLR7/8 agonist resiquimod (R848) T-cell stimulants IL-7 anti-PD-1 mAb tested enhance immune responses Results Spontaneous varied among subjects patients. LPS stimulation increased total 1,648% 1,929% Conversely, diminished 71% 61% IL-7, but not markedly both (127%) (79%). Dexamethasone also reduced anti-CD3/CD28 54%; while ameliorated dexamethasone-induced suppression. significantly enhanced lymphocyte function over 90% Conclusion can reveal host response patterns drugs selectively down– up-regulate patient immunity. Furthermore, detect effect specific independently regulate innate could enable precision-based

Language: Английский

---

New Criteria for Pediatric Sepsis: A Phoenix Rising

The Journal of Pediatric Pharmacology and Therapeutics, Journal Year: 2024, Volume and Issue: 29(6), P. 676 - 678

Published: Dec. 1, 2024

Language: Английский

---